KNSA · Kiniksa Pharmaceuticals International, plc · Stock research

AGIO

Agios Pharmaceuticals, Inc.

Mitapivat SCD label-expansion re-rate: positive RISE UP Phase 3 (2026-06-15) plus FDA Priority Review (2026-07-07) set a 2026-11-01 PDUFA binary. The acceptance pop is digested and backup asset tebapivat's 2026-07-21 Phase 2 failure thins the pipeline, so the tape drifts into a decision still three-plus months out.

CGEM

Cullinan Therapeutics, Inc.

CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout until 2H-2026 — a between-catalysts base, not a catalyst buy. The 2026-08-07 Q2 print is a cash/runway checkpoint, not a data event.

DSGN

Design Therapeutics, Inc.

Post-print collapse fully reversed: DSGN re-rated +40% in June to $15.19 (2026-07-10), reclaiming the $14.37 data-day high and pressing toward the $17.25 52-week high as the FA gene-therapy theme accelerated and the pipeline broadened (DT-168 FECD IND cleared, DT-818 DM1 dosing began 2026-06-30). Structure repaired from broken to constructive, but the next hard binary is the Q4-2026 registrational update — a name ~45% off its lows near highs sits in a data gap.

DYN

Dyne Therapeutics, Inc.

Neuromuscular RNA-conjugate name re-rating near its 52-week high ($25) on a de-risked path: z-rostudirsen DMD exon-51 BLA submitted 2026-05-26 with Priority Review requested. The FDA filing/Priority-Review decision (~late July) and the 2026-07-27 Q2 update are the near-term binary; FORCE conjugate modality sidesteps the AAV death risk that crushed the DMD field. ACCELERATING, but stacked into event risk.